IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v641y2025i8064d10.1038_s41586-025-08842-1.html
   My bibliography  Save this article

Re-adenylation by TENT5A enhances efficacy of SARS-CoV-2 mRNA vaccines

Author

Listed:
  • Paweł S. Krawczyk

    (International Institute of Molecular and Cell Biology)

  • Michał Mazur

    (International Institute of Molecular and Cell Biology)

  • Wiktoria Orzeł

    (International Institute of Molecular and Cell Biology
    University of Warsaw)

  • Olga Gewartowska

    (International Institute of Molecular and Cell Biology)

  • Sebastian Jeleń

    (International Institute of Molecular and Cell Biology
    University of Warsaw)

  • Wiktor Antczak

    (International Institute of Molecular and Cell Biology
    University of Warsaw)

  • Karolina Kasztelan

    (International Institute of Molecular and Cell Biology)

  • Aleksandra Brouze

    (International Institute of Molecular and Cell Biology
    University of Warsaw)

  • Katarzyna Matylla-Kulińska

    (International Institute of Molecular and Cell Biology
    University of Warsaw)

  • Natalia Gumińska

    (International Institute of Molecular and Cell Biology)

  • Bartosz Tarkowski

    (International Institute of Molecular and Cell Biology)

  • Ewelina P. Owczarek

    (International Institute of Molecular and Cell Biology)

  • Kamila Affek

    (International Institute of Molecular and Cell Biology)

  • Paweł Turowski

    (ExploRNA Therapeutics)

  • Agnieszka Tudek

    (Institute of Biochemistry and Biophysics)

  • Małgorzata Sroka

    (International Institute of Molecular and Cell Biology)

  • Tomasz Śpiewla

    (University of Warsaw)

  • Monika Kusio-Kobiałka

    (International Institute of Molecular and Cell Biology)

  • Aleksandra Wesołowska

    (Medical University of Warsaw)

  • Dominika Nowis

    (Medical University of Warsaw)

  • Jakub Golab

    (Medical University of Warsaw)

  • Joanna Kowalska

    (University of Warsaw)

  • Jacek Jemielity

    (University of Warsaw)

  • Andrzej Dziembowski

    (International Institute of Molecular and Cell Biology
    University of Warsaw)

  • Seweryn Mroczek

    (International Institute of Molecular and Cell Biology
    University of Warsaw)

Abstract

Despite the widespread use of mRNA vaccines against COVID-19, little is known about the metabolism of therapeutic RNAs. Here we use nanopore sequencing1–3 to analyse individual therapeutic mRNA molecules, focusing on their poly(A) tails. We show that the Moderna mRNA-1273 vaccine4 has a poly(A) tail of around 100 nucleotides, followed by an mΨCmΨAG sequence. In cell lines, mRNA-1273 undergoes rapid degradation initiated by mΨCmΨAG removal, followed by CCR4–NOT-mediated deadenylation. However, in medically relevant preclinical models, particularly in macrophages, mRNA-1273 poly(A) tails are extended to up to 200 nucleotides by the TENT5A poly(A) polymerase5–7, which is induced by the vaccine. Re-adenylation, which stabilizes target mRNAs, is consistently observed in synthetic mRNAs that encode proteins targeted to the endoplasmic reticulum, such as ovalbumin or antigens from Zika virus8 or the malaria parasite9. The extent of re-adenylation varies: the BioNTech–Pfizer BNT162b2 vaccine10 shows less potent re-adenylation than mRNA-1273, which correlates with a smaller proportion of membrane-associated BNT162b2. This highlights the crucial role of spatial accessibility to ER-resident TENT5A in determining re-adenylation efficiency. In vivo, TENT5A is expressed in immune cells that take up mRNA vaccine, and TENT5A deficiency reduces specific immunoglobulin production for mRNA vaccines after immunization in mice. Overall, our findings reveal a principle for enhancing the efficacy of therapeutic mRNAs, paving the way for improvement.

Suggested Citation

  • Paweł S. Krawczyk & Michał Mazur & Wiktoria Orzeł & Olga Gewartowska & Sebastian Jeleń & Wiktor Antczak & Karolina Kasztelan & Aleksandra Brouze & Katarzyna Matylla-Kulińska & Natalia Gumińska & Barto, 2025. "Re-adenylation by TENT5A enhances efficacy of SARS-CoV-2 mRNA vaccines," Nature, Nature, vol. 641(8064), pages 984-992, May.
  • Handle: RePEc:nat:nature:v:641:y:2025:i:8064:d:10.1038_s41586-025-08842-1
    DOI: 10.1038/s41586-025-08842-1
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41586-025-08842-1
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1038/s41586-025-08842-1?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:641:y:2025:i:8064:d:10.1038_s41586-025-08842-1. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.